Dr. Lee co-founded the company in May 2009 as a Board Member, President, and Chief Executive Officer. Prior to joining PharmTak, Inc., he was Chief Technical Officer and General Manager, Drug Products for Waterstone Pharmaceuticals, Inc. Dr. Lee was Vice President of Manufacturing at Replidyne, Inc. in Louisville, Colorado. During his stay in Replidyne, he was in charge of developing a topical product for an MRSA antibacterial, tablet and powder formulations of a new class antibiotic and a colonic delivery formulation for a new antibiotic.

Dr. Lee was Vice President, Development at Cellegy Pharmaceuticals in South San Francisco, California. Dr. Lee joined Cellegy in 1998 and built the Development Group to develop topical, transdermal, and skincare products. He was responsible for developing Nitroglycerin Ointment and Testosterone Transdermal Gel products during his stay in Cellegy, and both products were successfully marketed in 26 European and Asian countries. After the successful acquisition of Vaxis Therapeutics by Cellegy, Dr. Lee assumed the responsibility of overseeing the CMC of a developmental vaginal gel product for HIV prevention.

Prior to Cellegy, Dr. Lee worked as Director of Pharmaceutical Development at Cytel, Inc.; Division Director of Formulation Development at Oread Laboratories; and Director of Formulation Development at Syntex Research/Roche Global Development. Besides the Department Director position at Syntex/Roche, Dr. Lee also served as CMC Leader for five years for all Animal Health projects and one Human project. Dr. Lee’s effort at Syntex/Roche resulted in five FDA approved NDA/NADA. Dr. Lee is an author or co-author for a book chapter, 14 research papers or monographs, and 9 issued patents.

Dr. Lee received his M.S. and Ph.D. in Pharmaceutical Chemistry from the University of Kansas, Lawrence, Kansas.

Ms. Sue joined PharmTak in February 2011. She has more than 20 years of experience in pharmaceutical product development and in retail pharmacy as a pharmacist. Her expertise includes solid dosage form development and manufacturing, process scale up and validation, cGMP regulations, and FDA IND, NDA, and ANDA submissions.

Ms. Sue has product development experience in both branded and generic pharmaceutical products. As a consultant for several US pharmaceutical companies in the early 2000s, Ms. Sue assisted with drug development programs, conducted experimental design and data analysis to evaluate processing parameters, and developed products for several challenging new drug candidates. Before going into consulting, she was a senior scientist at Oread, Inc. responsible for project management, drug development problem solving, product manufacture for clinical studies, and preparation of product development reports.

Prior to joining Oread, Ms. Sue served in various management positions at Impax Laboratories, Inc. Her responsibilities included generic drug development focusing on controlled-release technologies, patent application, technology transfer, process scale up, and regulatory document preparation for FDA filing. While at Gilead Sciences, Inc., Ms. Sue was heavily involved in their first oral dosage form program from IND to NDA stages. She developed products suitable for toxicological assessments, clinical trials, and market launch. Prior to joining Gilead, Ms. Sue was a senior research chemist in Syntex Research. She was involved in a wide variety of formulation development projects of new chemical entities and participated in a team of senior scientists to develop strategic plans applicable for drug development process optimization.

Ms. Sue received her B.S. in Pharmacy from National Taiwan University in 1981 and her M.S. in Pharmaceutics from the University of Texas at Austin in 1984. She has six patents and seven publications.